echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Beihai Kangcheng's CAN008 injection for the treatment of glioblastoma (GBM) completed the first patient administration in a phase II clinical trial in China

    Beihai Kangcheng's CAN008 injection for the treatment of glioblastoma (GBM) completed the first patient administration in a phase II clinical trial in China

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Beihai Kangcheng Pharmaceutical Co.
    , Ltd.
    announced that its Phase II clinical study of CAN008 injection for the treatment of glioblastoma has completed the first patient administration in mainland China
    .

    This study is a multi-center, randomized, double-blind, placebo-controlled phase II clinical trial.
    Based on standard treatment (radiotherapy plus temozolomide (TMZ)), the efficacy of CAN008 and placebo was compared
    .


    In addition to effectiveness, the trial will also explore clinically relevant biomarkers to benefit the majority of GBM patients


    CAN008 is recognized by the drug regulatory agencies in major international markets as having potential prospects in the treatment of glioblastoma
    .


    Previously, CAN008 was certified as an orphan drug for the treatment of glioblastoma by the FDA and EMA


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.